A decisional algorithm to start iron chelation in patients with beta thalassemia.
作者信息
Danjou Fabrice, Cabantchik Zvi Ioav, Origa Raffaella, Moi Paolo, Marcias Michela, Barella Susanna, Defraia Elisabetta, Dessì Carlo, Foschini Maria Loreta, Giagu Nicolina, Leoni Giovan Battista, Morittu Maddalena, Galanello Renzo
出版信息
Haematologica. 2014 Mar;99(3):e38-40. doi: 10.3324/haematol.2013.098202.
Abstract
摘要
相似文献
1
A decisional algorithm to start iron chelation in patients with beta thalassemia.
Haematologica. 2014 Mar;99(3):e38-40. doi: 10.3324/haematol.2013.098202.
2
Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
Blood Cells Mol Dis. 2019 Jul;77:67-71. doi: 10.1016/j.bcmd.2019.03.007. Epub 2019 Apr 1.
3
Iron-chelating therapy for transfusional iron overload.
N Engl J Med. 2011 Apr 14;364(15):1476; author reply 1477. doi: 10.1056/NEJMc1101838.
4
Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Transfusion. 1999 Mar;39(3):333-4. doi: 10.1046/j.1537-2995.1999.39399219293.x.
5
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1.
6
A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
Br J Haematol. 2020 Nov;191(3):e81-e83. doi: 10.1111/bjh.17035. Epub 2020 Sep 18.
7
Evaluation and treatment of transfusional iron overload in children.
Pediatr Clin North Am. 2013 Dec;60(6):1393-406. doi: 10.1016/j.pcl.2013.09.003.
8
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.
9
Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Hematol Oncol Clin North Am. 2014 Aug;28(4):703-27, vi. doi: 10.1016/j.hoc.2014.04.004.
10
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28.
引用本文的文献
1
Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies.
J Clin Apher. 2022 Feb;37(1):100-105. doi: 10.1002/jca.21956. Epub 2021 Dec 13.
2
Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe -Thalassemia.
Biomed Res Int. 2020 Dec 13;2020:8185016. doi: 10.1155/2020/8185016. eCollection 2020.
3
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.
Haematologica. 2016 Jan;101(1):38-45. doi: 10.3324/haematol.2015.133983. Epub 2015 Sep 18.
4
The Labile Side of Iron Supplementation in CKD.
J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681/ASN.2015010052. Epub 2015 May 21.
5
Estimating tissue iron burden: current status and future prospects.
Br J Haematol. 2015 Jul;170(1):15-28. doi: 10.1111/bjh.13374. Epub 2015 Mar 12.
6
Labile iron in cells and body fluids: physiology, pathology, and pharmacology.
Front Pharmacol. 2014 Mar 13;5:45. doi: 10.3389/fphar.2014.00045. eCollection 2014.
本文引用的文献
1
The role of endocytic pathways in cellular uptake of plasma non-transferrin iron.
Haematologica. 2012 May;97(5):670-8. doi: 10.3324/haematol.2011.054858. Epub 2011 Dec 16.
2
Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
Am J Hematol. 2012 Jan;87(1):55-61. doi: 10.1002/ajh.22203. Epub 2011 Nov 28.
3
Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.
Br J Haematol. 2009 Dec;147(5):744-51. doi: 10.1111/j.1365-2141.2009.07907.x. Epub 2009 Sep 18.
4
High nontransferrin bound iron levels and heart disease in thalassemia major.
Am J Hematol. 2009 Jan;84(1):29-33. doi: 10.1002/ajh.21317.
5
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Haematologica. 2007 May;92(5):583-8. doi: 10.3324/haematol.10842.
6
Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients.
J Pediatr Hematol Oncol. 2006 May;28(5):311-5. doi: 10.1097/01.mph.0000212915.22265.3b.
7
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
J Cardiovasc Magn Reson. 2006;8(3):543-7. doi: 10.1080/10976640600698155.
8
LPI-labile plasma iron in iron overload.
Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. doi: 10.1016/j.beha.2004.10.003.
9
Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Blood. 2004 Sep 1;104(5):1504-10. doi: 10.1182/blood-2004-02-0630. Epub 2004 May 20.
10
Intracellular and extracellular labile iron pools.
Adv Exp Med Biol. 2002;509:55-75. doi: 10.1007/978-1-4615-0593-8_4.
Zotero 插件